Exdensur Injection, Solution
NDC Package 0173-0927-61

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Exdensur (depemokimab) injection is eXDENSUR is indicated for the add‑on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older.Limitations of UseEXDENSUR is not indicated for the relief of acute bronchospasm or status asthmaticus [see Warnings and Precautions (5.2)]. This formulation utilizes a injection, solution delivery system. Marketed by Glaxosmithkline Llc, this product is identified by NDC 0173-0927 and is authorized under FDA application BLA761458.

Identification & Billing

NDC Package Code
0173-0927-61
Package Description
1 SYRINGE in 1 CARTON / 1 mL in 1 SYRINGE
Product Code
0173-0927
11-Digit Billing Format
00173092761

Clinical Specifications

Proprietary Name
Exdensur
Non-Proprietary Name
Depemokimab
Substance Name
Depemokimab
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
DEPEMOKIMAB 100 mg/mL
Usage Information
EXDENSUR is indicated for the add‑on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older.Limitations of UseEXDENSUR is not indicated for the relief of acute bronchospasm or status asthmaticus [see Warnings and Precautions (5.2)].

Regulatory & Marketing

Labeler Name
Glaxosmithkline Llc
Product Type
Human Prescription Drug
FDA Application #
BLA761458
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
12-16-2025
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (0173-0927). Click a package code to view its specific billing and regulatory data.

0173-0927-42
1 SYRINGE in 1 CARTON / 1 mL in 1 SYRINGE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0173-0927-61 identifies a specific commercial package of 1 syringe in 1 carton / 1 ml in 1 syringe of Exdensur, a human prescription drug labeled by Glaxosmithkline Llc. This injection, solution is formulated for subcutaneous use and contains depemokimab as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Glaxosmithkline Llc on December 16, 2025. The current certification is valid through December 31, 2027.

How is this Glaxosmithkline Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00173092761. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0173-0927-61
11-Digit CMS (5-4-2)
00173-0927-61

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.